These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23343797)

  • 1. Optimal cytoreduction with neutral argon plasma energy in selected patients with ovarian and primitive peritoneal cancer.
    Renaud MC; Sebastianelli A
    J Obstet Gynaecol Can; 2013 Jan; 35(1):49-52. PubMed ID: 23343797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative Predictive Factors for Complete Cytoreduction and Survival Outcome in Epithelial Ovarian, Tubal, and Peritoneal Cancer After Neoadjuvant Chemotherapy.
    Baek MH; Lee SW; Park JY; Rhim CC; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Int J Gynecol Cancer; 2017 Mar; 27(3):420-429. PubMed ID: 28187098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary debulking surgery of the upper abdomen and the diaphragm, with a plasma device surgery system, for advanced ovarian cancer.
    Cordeiro Vidal G; Babin G; Querleu D; Guyon F
    Gynecol Oncol; 2017 Jan; 144(1):223-224. PubMed ID: 27836207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
    Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
    Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interval debulking surgery following neo-adjuvant chemotherapy for stage IVB ovarian cancer using neutral argon plasma (PlasmaJet™).
    Butler-Manuel S; Lippiatt J; Madhuri TK
    Gynecol Oncol; 2014 Dec; 135(3):622-3. PubMed ID: 25450152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.
    Nicklin JL; McGrath S; Tripcony L; Garrett A; Land R; Tang A; Perrin L; Chetty N; Jagasia N; Crandon AJ; Nascimento M; Walker G; Sanday K; Obermair A
    Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):651-658. PubMed ID: 28718942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
    Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
    Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
    Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
    Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
    Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
    Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 Mar; 116(3):364-9. PubMed ID: 19897231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Splenectomy as Part of Cytoreductive Surgery in Recurrent Epithelial Ovarian Cancer.
    Bacalbasa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Sep; 35(9):5097-101. PubMed ID: 26254413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.
    Phippen NT; Barnett JC; Lowery WJ; Miller CR; Leath CA
    Gynecol Oncol; 2013 Oct; 131(1):158-62. PubMed ID: 23872110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients.
    Sánchez-Iglesias JL; Perez-Benavente A; Correa-Paris A; De la Torre Fernandez de Vega J; Carbonell Socias M; Gil-Moreno A
    Gynecol Obstet Invest; 2019; 84(3):259-267. PubMed ID: 30428466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
    Manci N; Bellati F; Muzii L; Calcagno M; Alon SA; Pernice M; Angioli R; Panici PB
    Ann Surg Oncol; 2006 Dec; 13(12):1717-23. PubMed ID: 16957965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary versus secondary cytoreduction for epithelial ovarian cancer: a paired analysis of tumour pattern and surgical outcome.
    Braicu EI; Sehouli J; Richter R; Pietzner K; Lichtenegger W; Fotopoulou C
    Eur J Cancer; 2012 Mar; 48(5):687-94. PubMed ID: 21757333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.